https://platum.kr/archives/186160
Bioventure company RudaCure has secured a Series A investment of KRW 6 billion.
RudaCure is primarily developing dry eye disease and chronic pain treatments. The Series A round included Hanlim Pharmaceutical, Y&Archer Co., Ltd., and CKD Venture Capital as participating investors.
The investors stated that they decided to invest after highly evaluating the commercialization potential of RudaCure's dry eye disease treatment 'RCI001,' recognizing its faster tear secretion efficacy, corneal damage recovery capability, and superior instillation compliance and safety compared to commercially available competing drugs.
The dry eye disease treatment market has been growing steadily due to the recent advancement of digital technology and the widespread adoption of vision correction procedures. RudaCure's 'RCI001' achieves rapid drug onset while significantly reducing side effects such as elevated intraocular pressure.
